Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines
C. R. M. Asquith, N. Fleck, C. D. Torrice, D. J. Crona, C. Grundner, W. J. Zuercher
Abstract
We screened a series of 4-anilinoquinolines and 4-anilinoquinazolines and identified novel inhibitors of Mycobacterium tuberculosis (Mtb). The focused 4-anilinoquinoline/quinazoline scaffold arrays yielded compounds with high potency and the identification of 6,7-dimethoxy-N-(4-((4-methylbenzyl)oxy)phenyl)quinolin-4-amine (34) with an MIC90 value of 0.63-1.25 M. We also defined a series of key structural features, including the benzyloxy aniline and the 6,7-dimethoxy quinoline ring, that are important for Mtb inhibition. Importantly the compounds showed very limited toxicity and scope for further improvement by iterative medicinal chemistry.
02 /Specification & Classification
Click any tag to browse matching papers- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines Targeting Mycobacterium tuberculosis
S. Roy, T. Berida, … C. L. Stallings·bioRxiv·Nov 14, 2022
- Discovery of benzophenanthridine derivatives with potent activity against multidrug resistant Mycobacterium tuberculosis
Z. Sun, Y. C. Liang, … J. Sun·bioRxiv·Nov 7, 2022
- Exploiting NDH-2 Vulnerability: Quinolines as Antitubercular Agents
Shashikanta Sau, Rohit Kumar, … Nitin Pal Kalia·bioRxiv·Jun 8, 2026
- Identification of novel chemical scaffolds that inhibit the growth of Mycobacterium tuberculosis in macrophages
S. Ahmed, A. J. Manning, … T. Parish·bioRxiv·Sep 28, 2021
- Identification of cyclic hexapeptides natural products with inhibitory potency against Mycobacterium tuberculosis
S. B. Singh, J. Odingo, … T. Parish·bioRxiv·Mar 10, 2018
- In silico drug discovery strategies identified ADMET properties of decoquinate RMB041 and its potential drug targets against Mycobacterium Tuberculosis
K. E. Knoll, M. M. van der Walt, D. t. Loots·bioRxiv·Nov 17, 2021